share_log

Grail | 10-Q: Quarterly report

Grail | 10-Q: Quarterly report

Grail | 10-Q：季度报表
美股SEC公告 ·  2024/11/13 15:18

Moomoo AI 已提取核心信息

GRAIL reported Q3 2024 revenue of $28.7 million, up 38% year-over-year, driven by a 57% increase in Galleri test volume despite a 3% decrease in average selling price. Screening revenue grew 52% to $25.4 million while development services revenue declined 18% to $3.3 million. The company posted a net loss of $125.7 million, compared to $891.4 million in Q3 2023.The company implemented a restructuring plan in August 2024 to focus on its core MCED business and reduce costs, resulting in a 25% workforce reduction and $19 million in restructuring charges. Management expects the plan to generate approximately $120 million in annual cost savings and extend cash runway from second half of 2026 into 2028. The company ended the quarter with $853.6 million in cash and cash equivalents.GRAIL continues advancing its PMA submission for Galleri to the FDA while operating as an independent public company following its spin-off from Illumina in June 2024. The company received $932.3 million in disposal funding from Illumina and entered into various agreements to govern the ongoing relationship between the companies, including supply, tax, and stockholder arrangements.
GRAIL reported Q3 2024 revenue of $28.7 million, up 38% year-over-year, driven by a 57% increase in Galleri test volume despite a 3% decrease in average selling price. Screening revenue grew 52% to $25.4 million while development services revenue declined 18% to $3.3 million. The company posted a net loss of $125.7 million, compared to $891.4 million in Q3 2023.The company implemented a restructuring plan in August 2024 to focus on its core MCED business and reduce costs, resulting in a 25% workforce reduction and $19 million in restructuring charges. Management expects the plan to generate approximately $120 million in annual cost savings and extend cash runway from second half of 2026 into 2028. The company ended the quarter with $853.6 million in cash and cash equivalents.GRAIL continues advancing its PMA submission for Galleri to the FDA while operating as an independent public company following its spin-off from Illumina in June 2024. The company received $932.3 million in disposal funding from Illumina and entered into various agreements to govern the ongoing relationship between the companies, including supply, tax, and stockholder arrangements.
GRAIL报告2024财年第三季度营业收入为2870万美元，比去年同期增长38%，尽管平均售价下降了3%，但Galleri检测的成交量仍增长了57%。筛查收入增长52%，达到2540万美元，而开发服务收入下降18%，降至330万美元。公司报告净亏损为12570万美元，而2023年第三季度的净亏损为89140万美元。公司在2024年8月实施了一项重组计划，专注于其核心MCED业务并减少成本，导致25%的员工裁减和1900万美元的重组费用。管理层预计该计划将每年产生约12000万美元的成本节约，并将现金流延续从2026年下半年延长至2028年。公司在本季度末的现金及现金等价物为85360万美元。GRAIL继续推动Galleri的PMA提交给FDA，同时在2024年6月从Illumina独立后，以独立上市公司的身份运营。公司从Illumina获得了93230万美元的处置资金，并签订了多项协议以监管两家公司之间的持续关系，包括供应、税务和股东安排。
GRAIL报告2024财年第三季度营业收入为2870万美元，比去年同期增长38%，尽管平均售价下降了3%，但Galleri检测的成交量仍增长了57%。筛查收入增长52%，达到2540万美元，而开发服务收入下降18%，降至330万美元。公司报告净亏损为12570万美元，而2023年第三季度的净亏损为89140万美元。公司在2024年8月实施了一项重组计划，专注于其核心MCED业务并减少成本，导致25%的员工裁减和1900万美元的重组费用。管理层预计该计划将每年产生约12000万美元的成本节约，并将现金流延续从2026年下半年延长至2028年。公司在本季度末的现金及现金等价物为85360万美元。GRAIL继续推动Galleri的PMA提交给FDA，同时在2024年6月从Illumina独立后，以独立上市公司的身份运营。公司从Illumina获得了93230万美元的处置资金，并签订了多项协议以监管两家公司之间的持续关系，包括供应、税务和股东安排。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

独立文件9  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    燃石医学
    BNR
    -- 6.940
    Neuronetics
    STIM
    -- 4.360
    Personalis
    PSNL
    -- 5.510
    OncoCyte
    OCX
    -- 2.5600
    恩佐生化
    ENZ
    -- 0.545
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！